Drug
Inotersen
Inotersen: highest development phase Phase 3, developed by Ionis Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Inotersen NCT04136184 | Phase 3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy |
| Inotersen NCT01737398 | Phase 2/3 | FAP |
Latest
No recent events.
Follow Inotersen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.